Melatonin and Oxidative Stress in People With Parkinson's Disease Taking Levodopa
Tests melatonin against placebo in people with Parkinson's disease taking levodopa.
Plain-language title generated from the registry record
Registry title: Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients
Key facts
- Where
- Dhaka, BangladeshSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 85 years old?
Source: NCT07375693, who can take part
Where in Bangladesh
- Bangladesh Medical UniversityDhaka, BangladeshNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bangladesh Medical University
- Trial code
- NCT07375693
- Record updated
- 29 January 2026
- Original description
In Bangladesh Melatonin is currently used for insomnia. Its potential therapeutic benefits beyond sleep regulation. This study aimss to evaluate the effects of melatonin supplementation on oxidative stress markers, neuroinflammation and clinical outcomes in patients with Parkinson's disease. The main question it aims to answer:Read full original descriptionShow less
Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
In Bangladesh Melatonin is currently used for insomnia. Its potential therapeutic benefits beyond sleep regulation. This study aimss to evaluate the effects of melatonin supplementation on oxidative stress markers, neuroinflammation and clinical outcomes in patients with Parkinson's disease. The main question it aims to answer:
In patients with Parkinson's disease receiving levodopa, does melatonin supplementation, compared to levodopa treatment alone, improve the symptoms of PD over a 12 week of period.
Participants will:
Take Melatonin 10mg or placebo everyday for 3 months at night 30minutes before bedtime. Visit the clinic once every 6 weeks for checkups and tests keep a diary of their symptoms,UPDRS score. At the end of 12 weeks will reaper hs-CRP, MDA and GSH.
Inclusion: diagnosesd Parkinson's disease patients taking levodopa; mild to moderate PD pt according to Hohen and Yahr staging, stage-I,II,III; age:>45 years; both male and female.
Exclusion: Prior stereotactic surgery for PD; suffering from active malignancy; known hypersensitivity to melatonin; pt with autoimmune disease; has any clinically significant medical condition that could interfere with the subject's ability to safely participate in the study or to be followed; secondary causes of PD; Patients taking anticonvulsants, OCP, DMARD; pregnancy or lactating mother.